Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550342 | 0.83 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL2329877 | 0.74 | TP53 (0.40) | TRPV4 | |
| SCHEMBL2322538 | 0.69 | TRPA1 (0.39) | — | |
| SCHEMBL1550345 | 0.67 | TSHR (0.33) | TRPV4 | |
| SCHEMBL2329024 | 0.66 | ALDH1A1 (0.41) | — | |
| SCHEMBL2322425 | 0.63 | MGLL (0.36) | — | |
| SCHEMBL1550333 | 0.62 | MAPK1 (0.58) | — | |
| SCHEMBL1406667 | 0.62 | KMT2A (0.49) | TRPV4 | |
| SCHEMBL574545 | 0.61 | RAB9A (0.48) | — | |
| SCHEMBL2325459 | 0.61 | SMN1; SMN2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501940-B2 | Tetrahydrocinnoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100016325-A1 | TETRAHYDROCINNOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016325-A1 | TETRAHYDROCINNOLINE DERIVATIVES | CYP27A1, CYP11B1, DHCR7 | TRPV4 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.